CEEOR PUBLICATIONS
RESEARCH ARTICLES
Bušányová B, Vajter M, Kelifová S, Lišková P, Miková H, Breciková K, Žigmond J, Rogalewicz V, Tichopád A, Višňanský M, Šarkanová I.
Leber hereditary optic neuropathy in Czechia and Slovakia: Quality of life and costs from patient perspective.
Heliyon. 2024. VOLUME 10, ISSUE 11, E32296.
Tichopád A, Žigmond J, Jeseňák M, Solovič I, Breciková K, Rybář M, Rožánek M, Sedlák V.
Adherence to application technique of inhaled corticosteroid in patients with asthma and COVID-19 improves outcomes.
BMJ Open Respiratory Research 2024;11:e001874.
Hospodková P, Karásek P, Tichopád A.
Stakeholder Insights into Czech Performance-Based Managed Entry Agreements: Potential for Transformative Change in Pharmaceutical Access?
Healthcare. 2024; 12(1):119.
Hospodková P, Gilíková K, Barták M, Marušáková E, Tichopád A.
Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective.
Healthcare. 2023; 11(8):1179.
Tichopád A,
Partially Autonomous Information System Facilitating Performance-based Managed Entry Agreements in Slovakia.
2022 E-Health and Bioengineering Conference (EHB), Iasi, Romania, 2022, pp. 1-4, doi: 10.1109/EHB55594.2022.9991597.
Vrablík M, Šarkanová I, Breciková K, Šedová P, Šatný M, Tichopád A,
Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias.
PLoS ONE, 2023, 18(5): e0272883.
Müllerová J., Žigmond J.,
Mapovanie liečby dospelých pacientov s relapsujúcou alebo refraktérnou B-bunkovou akútnou lymfoblastovou leukémiou (B-ALL) na Slovensku.
Bratislava, CEEOR 2023. Vydané ako elektronická publikácia č. 2023/04, CEEOR, 2023, 15 s. ISBN 978-80-974515-3-0.
Šarkanová I., Szépe, V.,
Novorodenci so syndrómom krátkeho čreva v Slovenskej republike 2017 – 2021.
Bratislava, CEEOR 2023. Vydané ako elektronická publikácia č. 2023/03, CEEOR, 2023, 17 s. ISBN 978-80-974515-1-6.
Šarkanová I., Szarvašová, Z.,
Komplexné perianálne fistuly pri Crohnovej chorobe: Deskriptívna analýza veľkosti populácie v Slovenskej republike.
Bratislava, CEEOR 2023. Vydané ako elektronická publikácia č. 2023/01, CEEOR, 2019, 18 s. ISBN 978-80-974515-0-9.
Kolek V, Grygárková I, Koubková L, Skřičková J, Švecová J, Sixtová D, Bartoš J, Tichopád A.
Vinculin and metavinculin exhibit distinct effects on focal adhesion properties, cell migration, and mechanotransduction,
PLoS One, 2019 Sept 4
Kolek V, Grygárková I, Koubková L, Skřičková J, Švecová J, Sixtová D, Bartoš J, Tichopád A.,
Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell lung cancer in real-world set-up.,
PLoS One, 2017 Jul 21;12(7)
Tichopád A, Müllerová J, Jackowska T, Nemes E, Pazdiora P, Sloesen B, Štefkovičová M,
Cost Burden of severe community-acquired rotavirus gastroenteritis requiring hospitalization in the Czech Republic, Slovakia, Poland and Hungary: A retrospective patient chart review,
Value Health Reg Issues. 2016 Sep;10:53-60.
Koblížek V, Pečeň L, Zatloukal J, Kociánová J, Plutisnký M, Kolek V, Novotná B, Kocová E, Prachařová S, Tichopád A.,
Real-life GOLD 2011 implementation: The management of COPD lacks correct classification and adequate treatment,
PLoS One, 2014 Nov 1;9(9)
Mullins CD, Onwudiwe NC, de Araujo GT, Chen W, Xuan J, Tichopád A, Hu S,
Guidance document: Global pharmacoeconomic model adaption strategies,
Value in Health Regional Issues 2014, 7 – 13
Tichopad A, Roberts C, Gembula I, Hajek P, Skoczynska A, Hryniewicz W, Jahnz-Rozyk K, Prymula R, Solovič I, Kolek V,
Clinical and Economic Burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia,
PLoS One, 2013 Aug 6;8(8)
Tichopád A, Vítová V, Kořístek Z and Lysák D,
Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients,
Journal of Clinical Apheresis 7/8 2013
Müllerová J, Hlavinková L, Štefkovičová M,
Economic burden of pediatric patients hospitalized due to rotavirus gastroenteritis (Ekonomická záťaž u pediatrických pacientov vyžadujúcich hospitalizáciu z dôvodu rotavírusovej gastroenteritídy),
Farmakoekonomika a lieková politika 3/2013, Article in Slovak
Karen I, Svačina Š, Lžičařová L, Býma S, Tichopád A,
Safety and effectiveness profile of the XR form of metformin compared with the standard form in patients with type 2. diabetes mellitus in the Czech Republic (Bezpečnostní a účinnostní profil XR formy metforminů v porovnání se standardní formou u pacientů s diabetem mellitus 2. typu v ČR),
Practicus 2/2013, Article in Czech
Solovič I, Avdičová M, Szilágyiová M, Švihrová V, Ballóková A, Gembula I, Tichopád A,
Health and economics burden of pneumococal diseases of elderly population in Slovakia (Zdravotná a ekonomická záťaž pneumokokových ochorení u staršej populácie na Slovensku),
Respiro 1/2013
Tichopád A, Szitášová A, Árvaiová A, Gembula I,
Reduction of glycosylated hemoglobin levels with insulin analogs glargin and detemir in real-world practice of DM2 therapy: Pharmacoeconoomics perspective of the payer in Slovakia (Znižovanie hodnôt glykovaného hemoglobínu pomocou lnzulínových analógov glargin a detemir v bežnej praxl liečby diabetes mellltus 2. typu: Farmakoekonomická perspektíva platcu pre Slovensko),
Diabetes a Obezita 5/2011, Article in Slovak
BUSINESS ARTICLES
Z Prahy na Západ, firma Ceeor převzala evropský trh skupiny IMS Health a má 8 tisíc nových lékařů,
Forbes, 5/2015
Data hunters: Poor compliance costs lot of money (Lovci dat: Nedodržení léčby stojí příliš peněz),
Mladá fronta Dnes FEB 2. 2013, Article in Czech
Business interview with Ales Tichopad, General Director of CEEOR,
for the Czech Pharma Report, 11/2012
Sommermeyer H,
Sales force productivity enhancement by PromoMonitor®,
Pharm Business Magazine 3/2011
Gembula I,
Financial lose estimated from dropped down product detailings among the first ten most active generics manufacturers in the PrimCare market in Slovakia (Finančné vyjadrenie straty z nezrealizovaných produktových diskusií u desiatich najaktívnejších generických spoločností v rámci panelu PrimCare na Slovensku),
Pharm Business Magazine 9/2011, Article in Slovak
FOR PUBLIC
Tichopád A, Research, marketing or coruption? (Výzkum, marketing nebo korupce?), Medical Tribune 16/2012, Article in Czech
Tichopád A, What is the value of human life in money (Jakou hodnotu má lidský život v penězích), Medical Tribune 19/2012, Article in Czech
Tichopád A, Is it still realistic to reduce drug prices? (Jak moc je reálné ještě snížit ceny léků?), Medical Tribune 6/2013, Article in Czech
Tichopád A, Willingness to pay for health – subject undisclosed? (Ochota platit za zdraví – téma neveřejné?), Medical Tribune 16/2012, Article in Czech
POSTERS
Doctors` failure in observance of the COPD management guidelines: Case of the Czech Republic
(ISPOR Amsterdam 2014)
Modeled outcomes and overall costs of the 13-valent pneumococcal conjugate vaccine in the Tunisian national vaccination program
(ISPOR Amsterdam 2014)
Cost-effectiveness of 13-valent versus 10-valent pneumococcal conjugate vaccine use in Croatian national vaccination program
(ISPOR Amsterdam 2014)
Prevalence of invasive and superficial candida infections in Africa and Middle East; A systematic review and meta-analysis
(114th Meeting of the American Society for Microbiology, Boston 2014)
MRSA infection and colonization rates in Africa and the Middle East; A systematic review and meta-analysis
(16th International Congress on Infectious Diseases Cape Town 2014)
The implementation of GOLD 2011 among pulmonary specialists in the Czech Republic
(1st International Workshop on Lung Health, COPD: The New Paradigms Monaco 2013)
Cost burden of rotavirus gastro-enteritis requiring hospitalizations in the Czech Republic and in Slovakia
(ISPOR Dublin 2013)
Value of life: As perceived by physicians and the general public
(ISPOR Dublin 2013)
Cost-effectiveness of 13-valent versus 10-valent pneumococcal conjugate vaccine use in the Czech national immunization program
(ISPOR Dublin 2013)
Economic burden of community acquired pneumonia in older adults in the new EU countries of the Central Europe
(ISPOR Dublin 2013)
Cost-effectiveness of 13-valent versus 23-valent pneumococcal polysaccharide vaccine and no vaccination in The Czech national vaccination program
(ISPOR New Orleans 2013)
Cost-effectiveness of hematopoietic stem cell mobilization strategies in multiple myeloma and lymphoma patients in Czech Republic
(ISPOR Berlin 2012)
Burden of invasive pneumococcal diseases in older adults in the new EU countries of the Central Europe
(ISPOR Berlin 2012)
Burden of community acquired pneumonia in older adults in the new EU countries of the Central Europe
(ISPOR Washington 2012)
Economic burden of community acquired pneumonia in older adults in the new EU countries of the Central Europe
(ECCMID London 2012)